700
Participants
Start Date
August 31, 2002
Primary Completion Date
February 28, 2007
Study Completion Date
February 28, 2007
Intravenous topotecan/cisplatin
"Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5.~Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan."
Intravenous etoposide/cisplatin
"Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid.~Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3."
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Frankfurt (Oder)
GSK Investigational Site, Neubrandenburg
GSK Investigational Site, Waren
GSK Investigational Site, Greifswald
GSK Investigational Site, Rostock
GSK Investigational Site, Rostock
GSK Investigational Site, Stralsund
GSK Investigational Site, Hamburg
GSK Investigational Site, Hamburg
GSK Investigational Site, Stade
GSK Investigational Site, Hamburg
GSK Investigational Site, Großhansdorf
GSK Investigational Site, Borstel
GSK Investigational Site, Flensburg
GSK Investigational Site, Leer
GSK Investigational Site, Bremen
GSK Investigational Site, Bielefeld
GSK Investigational Site, Kassel
GSK Investigational Site, Marburg
GSK Investigational Site, Giessen
GSK Investigational Site, Greifenstein
GSK Investigational Site, Göttingen
GSK Investigational Site, Magdeburg
GSK Investigational Site, Wuppertal
GSK Investigational Site, Velbert
GSK Investigational Site, Herne
GSK Investigational Site, Bochum
GSK Investigational Site, Oberhausen
GSK Investigational Site, Dorsten
GSK Investigational Site, Duisburg
GSK Investigational Site, Duisburg
GSK Investigational Site, Krefeld
GSK Investigational Site, Coesfeld
GSK Investigational Site, Cologne
GSK Investigational Site, Cologne
GSK Investigational Site, Bonn
GSK Investigational Site, Bonn
GSK Investigational Site, Bonn
GSK Investigational Site, Trier
GSK Investigational Site, Mainz
GSK Investigational Site, Koblenz
GSK Investigational Site, Hemer
GSK Investigational Site, Hamm
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Offenbach
GSK Investigational Site, Wiesbaden
GSK Investigational Site, Limburg an der Lahn
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Ludwigshafen am Rhein
GSK Investigational Site, Mannheim
GSK Investigational Site, Löwenstein
GSK Investigational Site, Karlsruhe
GSK Investigational Site, Freiburg im Breisgau
GSK Investigational Site, Munich
GSK Investigational Site, Rosenheim
GSK Investigational Site, Wangen
GSK Investigational Site, Nuremberg
GSK Investigational Site, Regensburg
GSK Investigational Site, Passau
GSK Investigational Site, Bayreuth
GSK Investigational Site, Erfurt
GSK Investigational Site, Bludesch
GSK Investigational Site, Klagenfurt
GSK Investigational Site, Linz
GSK Investigational Site, Vienna
GSK Investigational Site, Cottbus
GSK Investigational Site, Chemnitz
GSK Investigational Site, Leipzig
GSK Investigational Site, Plauen
GSK Investigational Site, Halle
GSK Investigational Site, Jena
Lead Sponsor
GlaxoSmithKline
INDUSTRY